GovChime
Notice ID: d530a6cee29d48aa894eac0c6d236a3dSpecial Notice

TECHNOLOGY LICENSING OPPORTUNITY: SmartBind pH Switch

Responses closed . Full description on SAM.gov.

Overview

Response deadline
5:00 PM MST
Posted
November 13, 2025
Notice type
Special Notice
Set-aside
No Set aside used
NAICS
325413: In-Vitro Diagnostic Substance Manufacturing
Agency
Department of Energy

Notice details

Office
TRIAD - DOE CONTRACTOR
Place of performance
Los Alamos, New Mexico, 87545
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
S-133461
Notice ID
d530a6cee29d48aa894eac0c6d236a3d

Description

This innovation from scientists at Los Alamos National Laboratory is a significant improvement on a gold standard protein purification method that gently captures and releases antibodies using mild pH changes, making antibody purification safer, more efficient, and less damaging.

The Challenge:

Purifying antibodies — vital tools in medicine and research — typically relies on a protein called Protein G that latches onto them. However, getting the antibodies back off this molecular “magnet” requires very acidic conditions, which can damage both the antibodies and Protein G itself. This harsh process risks ruining expensive materials and reducing the effectiveness of critical therapies and tests.

Problems Solved:

Researchers engineered a pH-switchable version of Protein G that uses gentle changes in acidity (pH) to control when it releases antibodies, it now binds antibodies at a mildly acidic pH and releases at a mildly basic pH — eliminating the need for harsh chemicals. This innovation protects sensitive proteins, improves efficiency, lowers costs, and opens the door for safer, greener, and more effective antibody purification in both labs and industry.

Key Advantages:

  • Gentle elution conditions: Antibodies are released at a mild pH (~8.2) instead of harsh acidic conditions (~2.7), reducing damage to both the antibodies and the protein itself.
  • Improved antibody stability and yield: Preserving antibody structure increases reliability and effectiveness, which is especially critical for therapeutic and diagnostic use.
  • Switchable binding mechanism: pH-sensitive histidine residues allow for a controlled "on/off" switch based on pH, improving process control and reproducibility.
  • Cost-effective and scalable: Reduces loss of expensive antibodies and minimizes the need for post-purification repair or replacement, saving money in industrial applications.

Market Applications:

  • Biopharmaceuticals
  • Life Sciences Research
  • Bioprocessing and Manufacturing Tools
  • Veterinary and Agricultural Biotech

Development Status: TRL 4

US Provisional / Patent No. 10,954,275

LA-UR-25-29451

LANL Tech Partnerships: Unlock the Innovative Potential

Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.

LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov.

Note: This is not a call for external services for the development of this technology.

https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology

https://www.lanl.gov/engage/collaboration/feynman-center/tech-and-capability-search

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Marc Witkowski

Secondary Contact

Lindsay Augustyn

Documents

Files (1)

  • FCI-tech-summary-visual-SmartBind.png

    65 KBAdded in Special Notice version 1Posted
    Download

Lifecycle

  1. 1
    Version 1Special NoticeCurrent

    TECHNOLOGY LICENSING OPPORTUNITY: SmartBind pH Switch

    Notice d530a6cee29d48aa894eac0c6d236a3d on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations. The Opportunity: Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatment modalities. By enabling more precise control over where and how therapeutic gases are delivered, the platform has the potential to unlock new product categories, enhance combination treatment strategies and accelerate translation of gas-based therapeutics into high-value clinical markets. How it Works: The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies. Key Advantages: Localized delivery: Targets therapeutic gases to the intended site while minimizing systemic exposure. Controlled release: Designed for sustained, tunable dosing under physiological conditions. Improved safety margin: Aims to separate therapeutic effect from toxicity risk. Platform versatility: Applicable across oncology, cardiovascular, neurological and regenerative indications. Development optimization: Supported by predictive modeling to guide dose and design decisions. Partnership-ready architecture: Suitable for integration with drug-device combinations and existing treatment modalities. Market Applications: Oncology Therapeutics Industry Cardiovascular and Vascular Medicine Industry Neurology and Neurodegenerative Disease Sector Regenerative Medicine and Tissue Engineering Industry Medical Device and Drug-Device Combination Companies Biotechnology and Specialty Pharma Companies Computational Drug Development and Modeling Firms Development Status: TRL 2 US patent pending LA-UR-26-22810 LANL Tech Partnerships: Unlock the Innovative Potential Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products. LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov. Note: This is not a call for external services for the development of this technology. https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology m.lanl.gov/tech-search
80%
Special Notice12/04/2026
57%
Combined Synopsis11/27/2026
Phadia 250 Reagent and Consumables
57%
AwardedOpen
Combined synopsis/solicitation for Immunoassay Reagents, Supplies and Consumables to be used for patient testing on an existing Architect i1000 analyzer located at the Pathology and Laboratory Medicine Services in Southern Arizona VA Medical Center (VA Tucson).
57%
Combined Synopsis11/13/2026
Requesting procurement of a high-throughput FDA approved molecular diagnostic testing system and reagents through a rental purchase agreement. Purchase order is requested to order additional specific products throughout the year necessary to perform rapid syndromic infectious disease diagnostic panels.
57%
Market Research11/27/2026

Additional Details

Solicitation Number

S-133461

Archive Date

Dec 5, 2026

Office Address

Columbus, OH, 43201